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ABSTRACT 
Little is known about the ability of d-δ-tocotrienol to protect against obesity-induced 
inflammation. These studies were conducted to determine whether d-δ-tocotrienol inhibits high-
fat diet (HFD)-induced peripheral inflammation, and to explore potential mechanisms by which 
d-δ-tocotrienol affects inflammation. In two animal experiments, mice were fed a low-fat control 
diet, a high-fat control diet, or a HFD supplemented with d-δ-tocotrienol: 400 mg/kg diet 
(experiment #1) or 60 mg/kg body weight (experiment #2) for 14 weeks. Expression of 
inflammatory and anti-inflammatory markers was measured in liver and white adipose tissue, 
and phosphorylation of STAT3 was measured using western blot.  d-δ-tocotrienol mitigate HFD-
induced hepatic inflammation, despite having no effect on body weight, suggesting direct anti-
inflammatory effects of d-δ-tocotrienol independent of body weight loss. Mechanistic studies in 
3T3-L1 adipocytes indicated that d-δ-tocotrienol suppresses LPS-induced inflammation through 
down-regulating STAT3 signaling. The potential for d-δ-tocotrienol as a treatment of obesity and 
related metabolic diseases requires further investigation. 
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1
1 INTRODUCTION  
1.1 Obesity-induced inflammation 
1.1.1 Adipose tissue inflammation 
Adipose tissue (AT) is now recognized as more than simply a storage depot for excess 
energy.  The endocrine nature of AT has been well-established by the discovery of proteins, 
termed “adipokines”, that are produced and secreted by adipocytes. Adipokines can act 
locally in an autocrine/paracrine manner, or on distant tissues through their endocrine 
function. In addition to its endocrine nature, AT possesses various signaling receptors that 
establish bidirectional crosstalk with other parts of the body through the central nervous 
system (CNS) or traditional circulating hormones [1]. This crosstalk is carried out by a 
number of proteins produced by adipocytes, including leptin, TNFα, IL-6, MCP-1, 
adiponectin, plasminogen activator inhibitor 1 (PAI1), adipsin, acylation stimulating protein 
(ASP), and resistin, among others [1].  During high-fat diet feeding and obesity, adipocytes 
undergo hypertrophy, and adipocyte production of inflammatory cytokines becomes 
dysfunctional [2, 3]. During obesity, adipocytes display increased production of the pro-
inflammatory cytokines and chemokines, IL-6, TNFα, and MCP1, and decreased secretion 
of the anti-inflammatory cytokine, adiponectin [3-5].  This leads to a low-grade 
inflammation within the adipose tissue, and increased infiltration of the fat depot by 
inflammatory immune cells [6, 7].  
In normal, healthy adipose tissue there are several resident immune cells present, including 
macrophages. These native adipose tissue immune cells, including M2 macrophages, IL-4- 
and CD4+ Tregs among others, appear to exert protective effects against the development of 
metabolic dysfunction [8-11]. Functional diversity of adipose tissue macrophages (ATM) 
  
 
2
depends upon stimulation of leukocytes by local stimuli [12]. When administered in vitro or 
in vivo the inflammatory stimulators lipopolysaccharide (LPS) or IFN-γ induce macrophages 
to attain the classical pro-inflammatory (M1) state, generating a Th1 response to exaggerate 
obesity [13, 14]. However, when polarized to the M2 state, macrophages stimulate Th2 
cytokine response promoting IL-4 and IL-13, thus attenuating the classical inflammatory 
NF-κB dependent pathways [13, 14]. Activation and maintenance of the M2, or 
“alternatively activated” state of adipose tissue macrophages is intrinsically regulated by 
production of IL-4, PPARγ, PPAR δ, and regulation of lipid metabolism and mitochondrial 
activity [15].  
Obesity-associated inflammation, insulin resistance and pathogenesis is mediated by ATM. 
Phenotypic heterogeneity of these macrophages is characterized by their activation or 
polarization between M2 (alternative) and M1 (classical) state [6, 16, 17]. These 
macrophages are responsible for sensing, integrating and maintaining the microenvironment 
of fat depots [18]. Upon receiving specific stimulus, these macrophages polarize into M1 or 
M2 state. When stimulated with LPS or interferon gamma, M1 upregulates IRF5, priming 
Th1 innate immune response by producing IL-12, IL-23, TNF involved in activation of 
Th1and Th17 response [19, 20]. Alternatively, M2 becomes activated by production of 
immunomodulatory Th2 cytokines (IL-4 and IL-13), CD4+ T cells and eosinophil derived 
Th2 cytokines [9, 21]. With high-fat diet feeding and obesity, the adipose tissue immune cell 
population shifts to a more pro-inflammatory state [7]. The population shift from anti-
inflammatory (M2) macrophages to a more pro-inflammatory (M1) profile correlates with 
insulin resistance [22]. Variation in gene expression and ATM profile coordinates with 
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progression of IR mediated by accumulation of CD8+ T cells, Th1 polarization CD4+ T cells, 
natural killer, natural killer T cells, and mast cells [10, 23-25].  
1.1.2  Hepatic inflammation 
Similar to AT inflammation and obesity, non-alcoholic fatty liver disease (NAFLD) is also 
associated with elevated levels of M1/Th1 cytokines and infiltration of macrophages. 
Odegaard et al., and Kang et al., in 2008, suggested that modulation of PPARδ-dependent 
polarization of M2 NAFLD in mice [26, 27]. In obese and diabetic patients, the hepatic 
macrophages are largely accounted for by the presence of kupffer cells (KCs), with higher 
level of MCP-1 which serves recruitment of monocyte in liver. Monocytes mature and 
exaggerate obesity-induced hepatic inflammation and insulin resistance, thus stimulating 
hepatocyte lipogenesis, ceramide production and adipocyte lipolysis [28]. Obese individuals 
show higher proinflammatory cytokines (IL-6, IL-1β, TNF-α, MCP-1) in circulation, 
suggesting that obesity is the underlying cause of insulin resistance, where the paracrine 
function of MCP1 suppress PPARγ expression thus contributing toward insulin resistance 
[29-32]. Modulation of these proteins (IL-1β, TNF-α) potentially depends upon activation of 
JNK and IKKβ/NF-KB, protein kinase R and IKK signaling through classical receptor-
mediated signaling mechanism [29, 33-36].   
1.1.3 Link between obesity-induced inflammation and metabolic disease 
There is now strong evidence supporting the idea that obesity-induced inflammation leads to 
cardiovascular and metabolic diseases [37]. Increased systemic inflammation and 
inflammatory proteins like CRP, IL-6, PAI-1, VCAM-1, α1-glycoprotein is directly 
correlated with increase in body mass index (BMI) [38]. Additionally, accumulation of 
monocytes, macrophages, T lymphocytes and activated endometrium results in 
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cardiovascular disease [39]. Accumulated monocyte and macrophages promote lipid 
peroxidation of LDL through the production of ROS, and inflammatory cytokines like IL-
1β, TNFα and IL-6, resulting in endothelial dysfunction [40]. Defective endothelial 
membrane induce adhesion and transendothelial migration of monocytes [40]. Subsequently 
IL-1β, and TNF-α stimulate expression of VCAM-1 and ICAM-1, E selectin, and movement 
of monocytes into sub endothelial layer is regulated by MCP-1, and [41, 42]. Adhesion and 
accumulation of platelets leads to the formation of thrombus, contributing toward acute 
coronary infection and myocardial infraction [39]. According to Festa et al. (2000), chronic 
inflammation plays important role initiating insulin resistance to induce hyperinsulinemia 
[2]. Further insulin resistance leads to enhanced tumor growth (colorectal and endometrial), 
as reported by Women Health Initiative (WHI) and European prospective investigation into 
Cancer and Nutrition (EPIC) [43-46]. This increased risk of cancer is driven either by 
mitogen effect of hyperinsulinemia or by increased production of insulin like growth factor 
(IGF1) in circulation [47, 48], as concluded by Renehan et al (2004), Rinaldi et al (2010) 
and  using meta-analysis[46, 48]. In 2011 Eltzschig & Carmeliet characterized T2DM and 
obesity by increased production of inflammatory cytokines (IL-6 and TNFα) from AT [49]. 
Increased level of IL-6 correlated in patients with breast cancer, prostate cancer, B-cell 
lymphoma and myeloma [49-51]. Subsequently, TNFα solicited proliferation and 
progression of tumors by activating NF-kB pathway [52]. Together, studies indicate that 
obesity-induced inflammation may be a factor contributing to the development of 
cardiovascular disease, insulin resistance, type 2 diabetes, and cancer.  
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1.2 Tocotrienols  
Given the rising global obesity epidemic, the development of novel nutritional and 
pharmacological approaches to reduce the deleterious consequences of obesity has become a 
major focus of research initiatives. Despite these efforts, most treatments have proven 
ineffective, dangerous, or largely unsustainable. Tocotrienols have emerged as a natural 
treatment of several metabolic disorders, including inflammation [39]. Vitamin E is also 
referred to as tocochromanols because of the presence of chroman-6-ols in its two isoforms, 
the tocopherol and tocotrienol [53, 54]. Dietary tocotrienols  can be obtained from seed 
endosperm of monocots, a limited number of dicots, palm oil, and cereal grains such as 
wheat, rice, rice bran, and barley. Highest concentration of  tocotrienols can be obtained 
from Elaeis guineensis (800 mg/kg) through crude palm oil extract, primarily consisting of 
alpha (α), beta (β), delta(δ), and gamma (γ) tocotrienol [55].   
Since the recognition of alpha tocopherol as isoform of vitamin E, eight chemically distinct 
isoforms have been classified into two categories, consisting of alpha (α), beta (β), delta(δ), 
and gamma (γ)- tocopherol (TP) and α, β, δ, and γ-tocotrienol. These isoforms of tocotrienol 
are classified based on number and location of methyl group on chromanol rings (Figure 1). 
At the molecular level, the effects of tocotrienols  are mediated through transcriptional 
factors, translational and post-translational modifications [56]. Tocotrienols  exhibit strong 
antioxidant, anti-proliferative, anti-survival, proapoptotic, antiangiogenic and anti-
inflammatory activity [57].  
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Figure 1 Structural classification of alpha, beta, gamma and delta tocotrienols based on the number and location of methyl group. α- tocotrienol: 5,7,8, trimethyl;  β-tocotrienol: 5,8 dimethyl;  γ-tocotrienol: 7,8 dimethyl;  d-δ-tocotrienol: 8, monomethyl.  
The presence of the unsaturated side chain of the tocotrienols structure allows for effective 
penetration into tissues with saturated fatty layer such as brain and liver [57]. 
Mechanistically, absorption and distribution of  tocotrienols isoforms depends upon the 
binding affinity with signaling molecules in brain, liver, intestine and AT [58]. Once 
reached to the bloodstream and exposed to chain of free radicals, tocotrienols neutralize free 
radicals before oxidative damage can occur to cellular membranes. Moreover, tocotrienols 
have been shown to decrease serum cholesterol and reduce atherogenic apolipoprotein B 
O
CH3 CH3
CH3
CH3
CH3
OH
CH3
CH3
CH3
alpha-Tocotrienol   
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concentrations [58, 59]. At the tissue level, absorption takes place with the help of enzyme 
lipoprotein lipase, or via receptor-mediated endocytosis of lipoproteins [58]. Lipoprotein 
lipase then degrades lipid into remnant for absorption by liver and other peripheral tissues. 
Interestingly bioavailability of  tocotrienols is highest in adipose tissue followed by adrenal 
gland, suggesting potential involvement of d-tocotrienol  in ameliorating low grade chronic 
inflammation [58].  
According to Sylvester and Shah (2005), tocotrienols possesse a challenge in terms of there 
bioavailability since it can be difficult to obtain therapeutic level of γ- tocotrienols  in 
circulation [60]. The bioavailability of  tocotrienols increases when it is administrated with 
food, owing to the necessity of micelle formation for optimal tocotrienols absorption [61]. 
Regardless of it relatively low bioavailability, accumulation of tocotrienols  is high in AT, 
skin and peripheral tissue [62, 63]. Accumulated tocotrienols in AT remain metabolically 
active and effective against obesity due to its prolong stay in AT and slows rate of 
degradation [64]. This suggests that tocotrienols might have prominent effect against obesity 
and obesity-induced inflammation and metabolic disease.  
1.3 Anti-inflammatory properties of tocotrienols   
Anti-inflammatory activity of  tocotrienols has been studied extensively in cancer cell 
models. Though these studies provide promising evidence for there additional research, and 
is required to determine optimal isoforms and doses for understanding there mechanism of 
action. Inflammation involves cascade of reactions, led by the activation of transcription 
factors such as NF-κB, STAT3, and Hypoxia induced factor -1 (HIF-1) [65-71]. Activated 
transcription factors stimulate production of inflammatory markers such as  nitric oxide 
synthase (iNOS), cyclooxygenase (COX), nitric oxide (NO) and prostaglandin E2 (PGE2) 
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[72]. Activation of these factors are closely associated with enhance expression of IL-1, IL-
6, and IL-8, to promulgate inflammation. According to Jiang et al. 2008, long-chain 
carboxychromanols of vitamin E mediated ω- and β-oxidation of hydrophobic side chain to 
inhibit COX [73]. This underscores the importance of carboxylic acid on C-13 and the 
length of side chain, among the isoforms of tocotrienol and tocopherol with chromanol 
analogs, in inhibiting COX [73]. Additionally, tocotrienols  have been shown to suppress 
expression of NF-κB in diabetic rats and cancer cell lines [74, 75] , IL- 1 and [76], IL-6 in 
rats bones [77], IL-8 in angiogenesis and telomerase activity [78], iNO [79], and COX2 in 
cancer cells [73, 75].  Most studies utilized either γ-tocotrienol or tocotrienol-rich fractions 
of palm oil. Few studies examined the anti-inflammatory properties of  tocotrienols in 
models of obesity. Our study is novel in that it evaluates the anti-inflammatory effects of δ-
tocotrienol in two mouse models of obesity. 
Inflammation of AT is associated with infiltration of macrophages; however, administration 
of gamma- tocotrienol  has been shown to inhibit infiltration of macrophages, limits 
transformation of M2 to M1 macrophages in bone marrow derived macrophages, and 
suppresse conversion of monocytes to macrophages via multiple signaling pathways [79-
84]. α- Tocotrienol inhibits proteasome via activation of P27 and P57 in human monocyte 
cells, suppression of LPS induced NO and PGE2, NF-κB activation in human monocyte 
cells, and inhibition of VCAM-1 and ICAM-1 from vascular endothelium cells [79, 82-84]. 
Further, Wang et al. concluded that gamma TT suppresses activity of CEBP/alpha and NF-
κB in bone marrow derived macrophages when stimulated by LPS [85]. In addition, Li et al. 
suggested that tocotrienol-rich fraction of palm oil potentiates activation of PPARγ and 
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PPARα in macrophages and human THP-1 cells [86]. Together, studies conducted in vitro 
and in vivo model systems suggest that TT exhibit strong anti-inflammatory effects.  
1.4 Signal transducer and activator of transcription 3 (STAT3) and inflammation.   
STAT3 acts as DNA binding transcription factor that plays a vital role in proliferation (c-
fos, c-myc and cycin D1), invasion (e.g matrix metalloproteins-2), apoptosis (e.g bcl-xL and 
survivin), and angiogenesis (e.g VEGF) [33, 87-90]. Similar to other STAT family proteins, 
STAT3 also possesses a DNA binding domain, amino-terminus for tetramerization, and SH2 
domain for recruitment of receptors and carboxy-terminal transactivation domain. 
Activation of STAT3 occurs via phosphorylation at tyrosine residue 705 (Tyr705 or Y705) 
or at Serine-727 (Ser727 or S727), and results in formation of STAT3 homodimer along 
with SH2 and SHP domain and that is translocated into the nucleus [73, 87, 89-91]. These 
molecules get recruited to the receptor and activate JAK1, which phosphorylates Tyr705 of 
STAT3.  Phosphorylation of Tyr705 mediated by JAK1 drives STAT3 dimerization, and 
subsequent translocation into the nucleus, where they bind to gene promoters [92]. In 
contrast, phosphorylation at Ser727 is driven by various factors like tyrosine motifs, ERK1, 
2, p38, JNK and H-7 sensitive kinase [93], or by recruitment of transcription cofactors as in 
STAT1 [94]. Activation of STAT3 by phosphorylation on either Tyr705 or Ser 727 results 
in activation of downstream gene or signaling molecules such as Ras/Raf/MAP kinase and 
the phosphatidylinositol 3-kinase (PI3-kinase) [95]. 
 
STAT3-mediated inflammation in cancer cells is well characterized, while its role in obesity 
is obscure. Obesity-promoted development of hepatocellular carcinoma depends on the 
production of IL-6 and TNF-α, and subsequent activation of STAT3 [96].  STAT3 plays 
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crucial role in propagating inflammation by activating downstream pathways like epidermal 
growth factor (EGFR), and platelet derived growth factor receptor (PDGFR) [97, 98]. 
Activated STAT3 can cause enhanced expression of NF-kB upon activation by IL-6 [99-
101].  Activation of NF-kB depends upon RELA-p50 and REL, where RELA in nucleus 
cause acetylation of p300 (EP300) to activate STAT3 signaling [102, 103] in cancer cells. 
Additional activators of STAT3-induced inflammation includes IL-23, IL21, IL-6, COX2, 
IL-17 and IL-23 [100, 103-108].  
1.5 Tocotrienols and STAT3 
Tocotrienols have been shown to suppress cancer cell proliferation through downregulating 
STAT3 signaling.  γ-TT effectively suppressed proliferation of multiple myeloma cells by 
blocking activation of Src kinase and Janus kinase 1 (JAK1), regulators of STAT3 [109]. 
Accordingly, Liu et al., (2012) found that expression of STAT3 is proportional to S1P 
receptor expression (S1PR1) in tumor cells, upregulating IL-6 expression [110]. Inhibition 
of STAT3 by γ-tocotrienol in mesothelioma cells occur via redox-silent analog of α-
tocotrienol, 6-O-carboxypropyl-α-tocotrienol [32, 33].  γ-tocotrienol  has been shown to 
suppress STAT3 activity in human hepatocellular carcinoma (Hep3b) cells  [111]. Likewise, 
the literature support a possible anti-inflammatory effect of tocotrienols mediated through 
STAT3 signaling, but these studies were conducted in cancer cells. Inhibition of these 
activating factors may contribute toward prevention or restriction of obesity induced 
inflammation of peripheral tissue. According to Kannappan 2012, tocotrienol was able to 
suppress activation of Src kinase, Janus kinase 1 (JAK-1) and JAK2 the regulators of 
STAT3 by inducing expression of tyrosine phosphatase SHP-1 [109].   
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There have been a limited numder of studies to examine the effects tocotrienols in obesity-
induced inflammation in adipocytes [81, 112-114]. Further, there have been no studies 
examining the effects of d-δ-tocotrienol on HFD-induced inflammation in the liver. The 
purpose of this study was to determine if d-δ-tocotrienol inhibits HFD-induced inflammation 
in liver and adipose tissue, and to identify if STAT3 mediates any anti-inflammatory effects 
of d-δ-tocotrienol. Therefore, the following aims were pursued.  
 
Specific Aim #1. Test the hypothesis that d-δ-tocotrienol inhibits HFD-induced 
inflammation in liver and adipose tissue. Gene expression of inflammatory cytokines and 
immune cell markers will be measured in livers and adipose tissue from mice fed HFD with 
or without tocotrienol. Cell culture studies in 3T3-L1 adipocytes will identify whether d-δ-
tocotrienol can inhibit LPS-induced inflammation. 
 
Specific Aim #2.  Test the hypothesis that d-δ-tocotrienol inhibits STAT3 signaling in 
liver and adipose tissue of HFD-fed mice. pSTAT3Ttyr705 and pSTAT3Ser727 will be measured 
by immunoblot analysis from livers and adipose tissue of mice fed HFD with or without TT. 
Cell culture studies in 3T3-L1 adipocytes will identify whether d-δ-tocotrienol can inhibit IL-
6-stimulated STAT3 activation (phosphorylation).  
2 MATERIAL AND METHODS 
2.1 Animal studies 
Animal studies were conducted at the Department of Pathology, Texas Tech University 
Health Sciences Center (TTUHSC), Lubbock, TX, USA and tissues were provided by Dr. 
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Chwan-Li Shen. Experimental protocols were reviewed and approved by Institutional 
Animal Care and Use Committee at TTUHSC. 
2.1.1 Experiment #1  
Male C57BL/6 mice (Charles River Laboratories), aged 5-6 weeks, were fed a low-fat 
control diet (n=9), a high-fat control diet (n=12), or a high-fat diet supplemented with d-δ-
tocotrienol (400 mg/kg diet; n=9) for 14 weeks. All of the diets are tocopherol-free basal diet 
with TT added to tocopherol-free soybean oil for the groups receiving d-δ-tocotrienol.  Liver 
samples were harvested and flash frozen in liquid nitrogen.  
2.1.2 Experiment #2 
Male CD-1 mice (Charles River Laboratories), aged 5-6 weeks, were randomly assigned to 
one of three treatment groups: 1) low-fat diet (n=10), 2) high-fat diet vehicle (n=10); 3) high-
fat diet TT (n=10).  The mice in the HFD vehicle group received distilled water by oral 
administration 5 times per week. The mice in the HFD TT group received d-δ-tocotrienol (60 
mg/kg body weight) 5 times per week for 14 weeks.  The TT was DeltaGold product at 70% 
purity containing ~ 90% delta and 10% gamma-tocotrienol, and was generously provided by 
American River Nutrition (Hadley, MA). Liver and inguinal white adipose tissue (IWAT) 
were harvested and flash frozen in liquid nitrogen. 
2.2 Cell culture studies  
 3T3-L1 cells (ATCC) were cultured in high-glucose DMEM (Dulbecco’s modified Eagle 
medium) fortified with 10% FBS (fetal bovine serum albumin), 1% penicillin and 
streptomycin in a humidifier of 10% CO2 at 37oC. After 3T3-L1 preadipocytes reached 
confluence, cells were differentiated using medium with, 1 µg/ml insulin, 1 µM 
dexamethasone, and 0.5 mM IBMX. After 2-3 days of treatment with differentiation media, 
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media was changed to DMEM with 10% FBS and 1% penicillin and streptomycin, there after 
changed after 2 days until fully confluent (~10 days after induction of differentiation).  
Fully differentiated 3T3-L1 adipocytes were treated with variable concentrations of d-δ-
tocotrienol (0, 2.5, 5, 10, 25 and 50 µM) over-night in serum free media (SFM). Cells were 
treated with 20 ng/ml of IL-6 (Cell signaling technology) for 20 minutes, and protein was 
extracted for western blot analysis. In other 3T3-L1 studies, fully differentiated 3T3-L1 
adipocytes were treated with variable concentrations of d-δ-tocotrienol over-night in serum 
free media (SFM). Cells were then incubated for 24 hours with lipopolysaccharides (LPS).   
2.3 RNA extraction  
Liver tissue- RNA was extracted from liver samples using Qiagen RNeasy tissue kit 50, 
DNA digestion was performed to improve the purity of RNA and to avoid DNA 
contamination. Concentration of RNA was measured using Nanodrop (Core facility, 
Department of Biology). Isolated RNA was used to prepare cDNA using the protocol of 
Promega, containing initial concentration of 2 µg RNA. Prepared cDNA was diluted up to 
3.33 ng/µl for Real-time PCR.    
Inguinal white adipose tissue (IWAT) tissue – Approximately 80-100 mg of IWAT tissue 
was homogenized in cold Trizol reagent, and was centrifuge at 12000RPM for 30 minutes. 
Infranatant was transferred to spin columns provided in the Qiagen RNeasy Lipid Tissue kit.  
DNA digestion was performed to improve the purity of RNA and to avoid DNA 
contamination. Concentration of RNA was measured using Nanodrop (Core facility, 
Department of Biology). Isolated RNA was used to prepare cDNA using the protocol of 
Promega, containing initial concentration of 2 µg RNA.    
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3T3-L1 cells – LPS-treated cells were harvested for extraction of RNA using Trizol reagent. 
Cells were washed with PBS once, followed by addition of 300 µl of Trizol into each well of 
6 well plates. Plates were incubated on ice for 20 minutes. Cells were transferred into a new 
1.7ml tubes, 250 µL of chloroform were added to the tubes, and tubes were shaken 
vigorously for 10 sec.  Tubes were incubated at room temperature for 15 minutes. Tubes 
were centrifuged at 12,000 RPM for 15 min at 40C, and supernatant was transferred to a new 
tube.  550 µL of isopropanol was added to each tube, and tubes were  mixed by inversion.  
Tubes were incubated at room temperature for 15 minutes. Tubes were centrifuged at 12,000 
RPM for 30 min at 40C, and supernatant was removed without disturbing the pellet.  800 µL 
of cold 70% ethanol (prepared in nuclease free water) was added to each tube, and the 
solution was centrifuged at 12,000 RPM for 15 min at 40C.  The supernatant was removed, 
followed by quick spin for 2 min at 12,000 RPM, remove leftover ethanol. The tubes were 
incubated on ice for 10 min, followed by addition of 20 µL of nuclease-free water. RNA 
concentration and quality was measured using Nanodrop (Core facility, Department of 
Biology). Isolated RNA was used to prepare cDNA using the protocol of Promega, 
containing initial concentration of 2ug RNA. 
2.4 Real-time PCR 
Real-time PCR was performed on liver cDNA (3.33 ng/µl) using SYBR-green reagent. 
Expression of macrophage-associated markers [Emr1(F4/80), Itgam (CD11b), Itgax 
(CD11c)], inflammatory/anti-inflammatory markers (Ifng, Il2, Ccl2 (MCP-1), Il6, Tnf, Il1b, 
Il17, Il23, Il10), and the STAT3-specific markers [Stat3, Ccnd1 (Cyclin D1), Socs3, and 
Kfl5] was measured and normalized with cyclophilin (Ppia).  
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Real time PCR was performed on IWAT cDNA (3.33ng/ul) using SYBR-green reagent, 
expression of macrophage associated markers (Ccl2 (MCP-1), Emr 1(F4/80), Itgam 
(CD11b), Itgax (CD11c), inflammatory markers Il6 was measured and normalized with 
cyclophilin.  
Real time PCR was performed on 3T3-L1 cell treated with variable concentration of tocotrienol 
and LPS. Isolated RNA was used to prepare cDNA (3.33 ng/µl). mRNA expression of the 
inflammatory markers Tnf, Il6, Ccl2 and the anti-inflammatory cytokine, Il10 and was detected 
using SYBR green reagent and was normalized to cyclophilin . Primer sequences are found in 
table 1. 
Table 1 Primers used for gene expression studies.  Gene Forward Primer Reverse Primer 
Ccl2 5-GGAGAGACAGCGGTCGTA AG 5-CCAGCCGGCAACTGTGA Ccl5 5-GCTCCAATCTTGCAGTCGTG 5-GAGCAGCTGAGATGCCCATT 
Ccnd1 5-CAAGTGTGACCCGGACTGC 5-GCTCCCTACTCTCAGGGTGA 
Emr1 5-GTGCCATCATTGCGGGAT TC 5-GACGGTTGAGCAGACAGTGA 
Fgf21 5-AGCATACCCCATCCCTGACT 5-TCCTCCCTGATCTCCAGGTG 
Il1b 5-TGCCACCTTTTGACAGTGATG 5-TTCTTGTGACCCTGAGCGAC 
Il2 5-CATGCAGCTCGCATCCTGT 5- AAGTGGGGCTTGAAGTGGG 
Il6 5-ATGGATGCTACCAAACTG GAT 5-TGAAGGACTCTGGCTTTGTCT 
Il10 5-TAACTGCACCCACTTCCCAG 5-AGGCTTGGCAACCCAAGTAA 
Il17 5-TCTTGGGGCTGAGGTACAGA 5-GACATTGTCACCATCAGGCAG 
Ifng 5-GAGGTCAACAACCCACAGGT 5-GGGACAATCTCTTCCCCACC 
Itgax 5-GGGACGCTTACCTGGGTTAC 5-CCTGGAAATCTCTGCAGGTGT 
Itgam 5-CCACACTAGCATCAAGGG CA 5-CCCTGATCACCGTGGAGA AG 
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Klf5 5 –TGAACGTCTTCCTCCCTGAC 5–GGTCTGGTGGGAGCTGAATA 
Ppia  5-CTTCGAGCTGTTTGCAGACAAAGT 5-AGATGCCAGGACCTGTATGCT 
SOCS3 5-GCAGTTCCAGGAATCGGGG 5-GGAGAGACAGCGGTCGTAAG 
Stat3 5-GCCACGTTGGTGTTTCATAATC 5-TTCGAAGGTTGTGCTGATAGAG 
Tnf 5-TGTCTACTCCTCAGAGCCCC 5-TCTCTCAATTGACTGTAGGGCA 
 
2.5 Protein extraction and immunoblot analysis  
In order to determine the effect of d-δ-tocotrienol on STAT3 signaling in 3T3-L1 adipocytes, 
western blot analysis was performed for STAT3. Phosphorylation of STAT3 at Tyr705 and 
Ser 727 was measured using the protein extracted from 3T3-L1 cells. Fully differentiated 
3T3-L1 cells treated with d-δ-tocotrienol were treated with 300 µl of 
radioimmunoprecipitation assay (RIPA) buffer containing protease and phosphatase 
inhibitors. Plates were incubated in ice for 20 minutes.  Cell lysates were scraped and 
collected into microcentrifuge tubes, followed by centrifugation at 13,200 rpm for 30 minutes 
at 4°C.  The semitransparent solution between the pellet and the supernatant was pipetted 
into a new tube for protein estimation using Lowry Protein Assay. Approximately 40 µg of 
concentrated protein was diluted using 4X laemmli buffer and was boiled for 5 minutes at 
100°C.  
Prepared protein sample was loaded in precast gel (Criterion Precast) purchased from Bio-
Rad Laboratory, and electrophoresis was performed at 90-110V for 2.5-3hours. 
Electrophorotic gel was transferred to PVDF membrane overnight at 10V. Next day, PVDF 
membrane was washed with deionized water and was incubated in blocking buffer (5% BSA 
in TBSt) for 1hr followed by addition of primary antibody prepared in 5% BSA 
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(pSTAT3Tyr705 and pSTAT3Ser727 in 5% BSA and total STAT3 in 1% BSA). Incubated for 1 
hr at 4°C, followed by 3 washes for 5 minutes each. Secondary antibody was added to the 
membrane (secondary Ab is anti-rabbit in 1% or 5% BSA or NFDM) and incubate for one 
hour, followed by 3 wash (5min each) by TBSt. Membrane was loaded with ECL for 
5minutes and was rushed to ImageQuant LAS4000 equipment and software (GE Healthcare). 
pSTAT3Tyr705 and pSTAT3Ser727 was purchased from Cell Signaling Technology (Danvers, 
MA), STAT3 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).  Band 
intensity and density was quantified using ImageJ (software) and were normalized with total 
STAT3.  
2.6 Enzyme-linked Immunosorbent Assay (ELISA)-  
Serum was obtained from mice in experiment # 2 at the end of the study. Serum adiponectin 
concentrations were analyzed using an ELISA kit from EMD Millipore Corporation 
(Billerica, MA, USA) per manufacturer’s instructions.  
2.7  Statistical analysis 
RT-PCR data was analyzed using one-way ANOVA. Turkey’s multiple comparison was used 
to identify significant differences between the groups. Western blot was analyzed by two-
way ANOVA. Data were analyzed using Prism software (version 7.0, GraphPad, La Jolla, 
California).  
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3 RESULTS 
3.1 Background Information  
3.1.1 Body weight –  
In experiment #1, the C57BL/6 mice fed the HFD gained significantly more weight than 
the LFD-fed controls, and d-δ-tocotrienol (400 mg/kg diet) had no effect on body weight (Fig 
2A). In experiment #2, the CD-1 mice fed with HFD for 14 weeks gained weight significantly 
compared to the LFD-fed controls, and in this study, d-δ-tocotrienol (60 mg/kg body weight) 
slightly, but significantly attenuated the HFD-induced increase in body weight (Fig 2B). EWAT 
was weighed in experiment #2, and HFD increased EWAT weight, and d-δ-tocotrienol had no 
effect on fat pad weight (Fig 3).    
           Figure 2  A) Body weight of C57BL/6 mice fed with normal chow diet (LFD), high fat diet (HFD) or HFD supplemented with d-δ-tocotrienol (400 mg/kg diet) for 14 weeks.  B) Body weight of CD-1 mice LFD, HFD or HFD and d-δ-tocotrienol (60 mg/kg body weight) for 14 weeks. Values are means ± SEM, n=9-12.     
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        Figure 3 CD-1 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (60 mg/kg body weight), epididymal white adipose tissue was collected and measured after completion of study. Values are means ± SEM, n=9-10.  
3.2  Anti-inflammatory effect of d-δ-tocotrienol in liver  
HFD-fed mice showed increased expression of some inflammatory markers when 
compared with LFD-fed control mice. Monocyte chemoattractant protein-1 (MCP-1 or Ccl2) 
expression was significantly increased by HFD, but this increase was suppressed by d-δ-
tocotrienol (400 mg/kg diet) in liver tissue (Fig 4). Hepatic expression of Emr1 was reduced 
when TT was administered orally at 60 mg/kg body weight (Fig. 5A), but not when given at 400 
mg/kg diet (Fig 5B). Likewise, expression of the inflammatory macrophage marker, Itgax, was 
increased in the liver by HFD (Fig. 6A & B). While tocotrienol  administered at a dose of 400 
mg/kg diet had no significant effect on Itgax expression (Fig. 6A), 60mg/kg body weight TT 
administered orally prevented the HFD-induced increase in Itgax (Fig. 6B). Tocotrienol  tended 
to reduce hepatic expression of Itgam (CD11b), but this did not reach statistical significance (Fig 
6C).  
 
0
1
2
3
4
5
EW
AT
 we
igh
t (g
) LFDHFD
HFD+60mg/kg BW
a
b
ab
  
 
20 
 
Figure 4 Hepatic Ccl2 (MCP-1) mRNA expression in 14 weeks old C57BL/6 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (400 mg/kg diet), Values are means ± SEM, n=7-9        
           Figure 5  A) Hepatic Emr1 (F4/80) mRNA expression CD1 mice fed LFD, HFD, and HFD with d-δ-tocotrienol (60 mg/kg body weight). B). Hepatic Emr1 (F4/80) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet), n=7-9 Values are means ± SEM, n=8-10      
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  Figure 6  A) Hepatic Cd11c (ITGAX) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet), n=7-9 B). Hepatic Cd11c (ITGAX)  mRNA expression CD1 mice fed LFD, HFD, and HFD with d-δ-tocotrienol (60 mg/kg body weight), Values are means ± SEM, n=8-10 C) Hepatic Cd11b (ITGAM) mRNA expression in 14 weeks CD1 mice fed with LFD, HFD and d-δ-tocotrienol (60 mg/kg body weight), n=8-10. Values are means ± SEM  400 mg/kg diet d-δ-tocotrienol supplementation suppressed the HFD-induced increase in 
hepatic Tnf-α (Fig 7) and Il2 (Fig 8) mRNA expression. d-δ-tocotrienol supplementation had no 
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significant effect on expression of Il6 (Fig 9), Il23 (Fig 10) Interferon-gamma (Fig 11), Il10 
(Fig.12) or Il-1beta (Fig 13).  
 
 Figure 7 Hepatic Tumor necrosis factor- alpha (TNF-α) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9   
 Figure 8 Hepatic Interleukin-2 (IL-2) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9   
 
Figure 9 Hepatic Interleukin-6 (IL-6) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9  
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   Figure 10 Hepatic Interleukin-23 (IL-23) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9   
 
Figure 11 Hepatic Interferon-gamma (Ifn-γ) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9   
 Figure 12 Hepatic Interleukin-10 (IL-10) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9 
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 Figure 13  Hepatic Interleukin-1beta (IL-1beta) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9  STAT3 associated inflammatory genes – To understand the role of STAT3 in mediating 
systemic inflammation during obesity, we analyzed expression of Stat3 target genes. There was 
no effect of d-δ-tocotrienol on STAT3 or its target genes like IL-17 (Fig 15), Cyclin D1(Fig 16) 
and Krüppel-like factors 5 (Fig 17) in the liver, except for Socs3. Expression of SOCS3 was 
sifnaficantly suppressed by d-δ-tocotrienol (Fig. 18).   
 
 
Figure 14 Hepatic Stat3 mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9.    
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 Figure 15Hepatic Interleukin-17 (IL-17) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9.   
 
Figure 16 Hepatic Cyclin D1 mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9.  
 
Figure 17 Hepatic Krüppel-like factors (KLF5) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9.  
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 Figure 18 Hepatic Suppressor of cytokine signaling 3 (SOCS3) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (400 mg/kg diet). Values are means ± SEM, n=7-9.   
3.3 Anti-inflammatory effect of d-δ-tocotrienol in inguinal white adipose tissue (IWAT) 
Administration of d-δ-tocotrienol (60 mg/kg body weight) had no effect on the HFD-
induced increase in MCP-1 expression (Fig 19) in IWAT tissue.  Similar effects were observed 
with Emr1 (F4/80) (Fig 20), Cd11b (ITGAM) (Fig 21) and Cd11c (ITGAX) (Fig 22), and Il6 
(Fig 23), though strong trends towards reductions in expression of Itgam (CD11b),  and Itgax 
were observed in IWAT of TT-supplemented mice. 
  
Figure 19 IWAT Ccl-2 (MCP-1) mRNA expression in C57BL/6 mice fed with LFD, HFD, and d-δ-tocotrienol (60 mg/kg body weight). Values are means ± SEM, n=7-9. 
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Figure 20 IWAT Emr1 (F4/80) mRNA expression in 14 weeks old CD-1 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (60mg/kg body weight), Values are means ± SEM, n=7-9.  
  
Figure 21 IWAT Cd11c (Itgax) mRNA expression in 14 weeks old CD-1 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (60mg/kg body weight), Values are means ± SEM, n=7-9. 
  
Figure 22 IWAT Cd11b (Itgam) mRNA expression in 14 weeks old CD-1 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (60mg/kg body weight), Values are means ± SEM, n=7-9.   
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Figure 23 IWAT Interleukin -6 (Il6) mRNA expression in 14 weeks old CD-1 mice fed with normal chow diet (LFD), high fat diet (HFD) and d-δ-tocotrienol (60mg/kg body weight), Values are means ± SEM, n=7-9.  
3.4 . STAT3 Phosphorylation in 3T3-L1 Adipocytes –  
To test whether d-δ-tocotrienol can suppress LPS-induced inflammation in cultured adipocytes, 3T3-
L1 adipocytes were cultured overnight in variable concentrations of d-δ-tocotrienol followed by 24 
hour incubation with LPS (10 µM). As expected, LPS increased expression of Il6, Tnf, and Ccl2 (Fig 
24 A-C). Treatment of 3T3-L1s with d-δ-tocotrienol decreased expression of Tnf and Ccl2 (Fig 24 B 
& C). Surprisingly, d-δ-tocotrienol had no effect on LPS-induced Il6 expression (Fig 24A).  
Interestingly, 50 µM d-δ-tocotrienol increased expression of the anti-inflammatory cytokine, IL-10 in 
LPS-treated adipocytes (Fig 25). 
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Figure 24. mRNA expression of A) Il-6  B) Tnf-α  C) Ccl2 (Mcp-1) in 3T3-L1 cells treated with different concentration of d-δ-tocotrienol overnight followed by addition of LPS (10 μg/ml) for 24 hr to induce inflammation. * represents significant difference compared to LPS-treated cells receiving vehicle.     
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Figure 25 mRNA expression of Interleukin-10 (IL-10) in 3T3-L1 cells treated with different concentration of d-δ-tocotrienol overnight followed by addition of LPS (10 μg/ml) for 24 hr to induced anti-inflammation response. * represents significant difference compared to LPS-treated cells receiving vehicle.   
To determine signaling mechanisms mediating the anti-inflammatory effects of d-δ-tocotrienol on 
Tnf expression in 3T3-L1 adipocytes, phosphorylation of the inflammatory transcription factor, 
STAT3, was measured. d-δ-tocotrienol had variable effects on basal and IL-6-induced STAT3 
signaling in 3T3-L1 adipocytes depending on the concentration used.  Higher concentrations of 
TT reduced basal and IL-6-induced STAT3 phosphorylation at Tyr705 and Ser727 (Fig 26). 
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  Figure 26 3T3-L1 cells treated with different concentration of d-δ-tocotrienol overnight followed by addition of IL-6 (20 ng/ml) for 20 minutes to induce STAT3 activation. * mark represents significant difference between control receiving vehicle or d-δ-tocotrienol and # represents significant difference compared to IL-6-treated cells receiving vehicle    
3.5 Serum adiponectin concentrations 
To test whether anti-inflammatory effects of δ-tocotrienol in vivo were mediated through 
increases in concentrations of the anti-inflammatory adipokine, adiponectin, adiponectin 
concentrations in the serum of mice from experiment #2 were measured. There was no effect of 
HFD or TT on circulating adiponectin concentrations (Fig 27).  
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Figure 27 Effect of d-δ-tocotrienol on circulating adiponectin in CD-1 mice fed a LFD, HFD, or HFD with d-δ-tocotrienol (60 mg/kg body weight). Values are means ± SEM, n=7-9. 
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4  DISCUSSION 
Obesity, inflammation and metabolic syndromes are closely associated, each being 
characterized by increased production of inflammatory cytokines, interacting with various 
inflammatory signaling pathways [115] . Obesity-induced low grade systemic inflammation 
contributes toward the development of NAFLD, characterized by accumulation of fat in liver 
with increased free fatty acids, reactive oxygen species, TNF-α, and enhanced activity of 
signaling molecules like IL-6, resulting in insulin resistance [116]. Development and progression 
of NAFLD primarily depends on a complex crosstalk between different organs and cells. This 
crosstalk is established by some major signaling pathways, including NFkB, AMPK, 
JAK/STAT, PPARs, PI3K, PKB/Akt, and Toll-like receptor (TLR) resulting in IR, oxidative 
stress and inflammation [117]. The ability to inhibit or suppress pace of any of these pathways 
will help us to ameliorate the effect of obesity-induced hepatic inflammation and steatosis.   
 
In our experiment, d-δ-tocotrienol suppressed the high-fat diet-induced increase in 
expression of Ccl2, Emr1, Cd11c, and CD11b  in liver.   However, not all inflammatory markers 
we measured followed this pattern.  To our knowledge, there have been no studies examining 
anti-inflammatory properties of d-δ-tocotrienol in liver of high-fat diet-fed animals.  Though 
further investigation is required, these data provide evidence that d-δ-tocotrienol holds promise 
as a natural therapeutic for obesity-related inflammation.  
 
Extensive studies on the endocrine nature of WAT has revealed that WAT is a complex 
organ that has the ability to integrate with other systems. While the nature of obesity-induced 
inflammation is complex, it is known that obesity-associated inflammation comes about, in part, 
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due to the secretion of inflammatory cytokines (IL-6, TNF-alpha, MCP-1) either from adipocytes 
or immune cells whose presence in WAT and liver increases during obesity. These WAT-derived 
inflammatory cytokines simulate production of inflammatory markers from immune cells located 
in liver and other organs [118, 119]. These cytokines include MCP-1, TNF-α, IL-1, IL-6 and IL-
8. These inflammatory molecules have been shown to activate c-Jun NH2-terminal kinase (JNK), 
phosphorylating IRS-1 at Ser 307, which has been linked to obesity-induced insulin resistance, 
metabolic disorders, CVD, and cancer [80, 81, 114, 120-123].  Downregulation of obesity-
induced adipose tissue inflammation has the potential to ameliorate a number of obesity-
associated metabolic diseases. 
 
Though strong trends were seen regarding d-δ-tocotrienol-induced suppression of 
expression of the inflammatory immune cell markers Itgam and Itgax, d-δ-tocotrienol had no 
significant effects on inflammatory markers in IWAT of mice.  These results are  not in 
accordance with Zhao et al., (2015), who reported that γ-tocotrienol administered by oral gavage 
to mice for 4 weeks decreased inflammatory gene expression in mice fed a HFD [81]. There are 
some differences between the study designs. For instance, Zhao et al. used γ-tocotrienol, while 
our study used δ-tocotrienol.  Further, Zhao et al. studied the epididymal WAT, while we used 
inguinal WAT. There is evidence that visceral adipose tissue contains more inflammatory and 
immune cells than subcutaneous adipose tissue  [124].  Therefore, the use of a subcutaneous 
depot may have masked any anti-inflammatory effects of d-δ-tocotrienol.  Despite not seeing 
effects on adipose tissue inflammation in vivo, we did see an effect of d-δ-tocotrienol to suppress 
LPS-induced inflammation in cultured adipocytes.  Similar findings were seen in Matsunaga et al 
(2012) when 3T3-L1 adipocytes were cultured in the presence of γ-tocotrienol with or without the 
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inflammatory stimulus, TNF-α [114].  Our data are novel in that d-δ-tocotrienol has not been tested 
for its anti-inflammatory properties in cultured adipocytes.   
 
γ-tocotrienol has been shown to suppress STAT3 signaling in cancer cell lines [109, 111, 
125-127].  Only one study, to our knowledge, has shown that d-δ-tocotrienol inhibits STAT3 
signaling, and this was conducted in a model of human bladder cancer.  We therefore wanted to 
test whether the anti-inflammatory effects of d-δ-tocotrienol in 3T3-L1 adipocytes was mediated 
through downregulation of STAT3.  Interestingly, we did see that some concentrations of d-δ-
tocotrienol suppressed basal and IL-6-induced STAT3 phosphorylation, and hence activation, in 
3T3-L1 adipocytes.  These data suggest that STAT3 may be the mechanism behind the anti-
inflammatory effects of d-δ-tocotrienol in cultured adipocytes. Future studies are needed to see if 
d-δ-tocotrienol inhibits STAT3 in vivo. 
 
NF-kB, a multiprotein transcription factor regulating secretion of TNFα and MCP-1, 
which phosphorylate and degrade inhibitory IKB1 or IKB2, activating NF-kB to travel into the 
nucleus and activate NF-kB-dependent transcription factors modulating activity of target genes 
[128-133]. Tocotrienol has been shown to suppress constitutively active NF-kB in mammalian 
epithelial cell line, prostate cancer, multiple myeloma, and colon cancer [74, 134-136].  While 
we did not explore NF-kB, it is possible that this inflammatory transcription factor could be an 
additional mediator of the anti-inflammatory effects of d-δ-tocotrienol seen in the liver and 
adipocytes. 
 
We postulated that d-δ-tocotrienol may have a global impact by enhancing secretion of 
the anti-inflammatory adipokine, adiponectin.  We found no effect of HFD or d-δ-tocotrienol on 
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serum adiponectin concentrations.  Our data are in accordance with the literature.  It has been 
shown before that chronic (4 months) HFD feeding had no effect on serum adiponectin 
concentrations in mice  [137].  Further, Zhao et al 2015) found no effect of γ-tocotrienol on 
serum adiponectin concentrations in mice fed a HFD [81, 138].    
The majority of studies on STAT3 and its signaling pathways have been studied in cancer 
cells, where its activation is in response to IL-6, IL-10, IL-17/23 family of cytokine [139]. 
Suppressor of cytokine signaling 3 (SOCS3) is a downstream target of STAT3. SOCS3 is key to 
suppress or promote inflammation depending upon the method of STAT3 activation (either via 
gp130 family cytokine or by IL-10 cytokine family) [140].  d-δ-tocotrienol suppressed 
expression of SOCS in liver, indicating potential downregulation of STAT3 signaling.  However, 
not all STAT3 target genes were downregulated, suggesting potential alternative signaling 
pathways downstream of STAT3.  
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5 CONCLUSION 
Our data suggest that d-δ-tocotrienol decreases expression of some inflammatory markers 
in liver, but not IWAT of mice fed a HFD. d-δ-tocotrienol also has direct effects on adipocytes to 
suppress LPS-induced inflammation and IL-6-induced STAT3 signaling.  Further studies are 
needed to determine the optimal isoform, dose, and treatment time of tocotrienol as a potential 
treatment for obesity-induced inflammation.  
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